Clinicians should consult literature so treatment options are current

Article

If the diploma on your office wall isn't freshly minted, chances are many of the decisions you make every day are based on outdated information from your optometry school classes.

Atlanta-If the diploma on your office wall isn't freshly minted, chances are many of the decisions you make every day are based on outdated information from your optometry school classes.

"There are a number of things we were taught during our training that, on reflection and further study, we find are no longer true or were never true, but rather based upon opinion and not fact," said Joseph Sowka, OD, FAAO, Diplomate, at the SECO meeting.

Myth: Dilate blood pressure patients

For example, clinicians have long been hesitant to dilate patients with markedly elevated blood pressure, particularly using an agent such as phenylephrine. The fear was that the drug, even at a low concentration of 2.5%, would further elevate blood pressure and put patients at risk of a cardiac event, Dr. Sowka said.

"There's never been any support behind this concept," he added. "When you look in the literature, there have been no adverse effects to patients using this agent at this concentration."

Myth: Dilating pregnant patients

Clinicians are also concerned about dilating patients who are pregnant or nursing. Their unease is due to the fear of teratogenic effects to the unborn child or the possibility of toxicity or other life-threatening effects to the newborn.

"When risks are outweighed by benefits of either dilation or therapeusis, this sometimes needs to be done," Dr. Sowka added. "But it should be done with informed consent from the patient and possibly in consult with the obstetrician."

He said that the highest potential for teratogenicity to the fetus is in the first trimester.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD; detailed what optometrists can expect to change when HB 1353's regulations are enacted later this year.
Arkansas Optometric Association legislative cochairs Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD, discuss their involvement in their bill and provide context for its relevance.
Elise Kramer, OD, FAAO, FSLS, describes her take on a multidisciplinary approach to dry eye
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Rachelle Lin, OD, MS, FAAO
Paul Karpecki, OD, FAAO
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
© 2025 MJH Life Sciences

All rights reserved.